Heartflow’s Patent Fight Suggests Imaging AI Competition Is Entering a New Phase
Heartflow is suing a competitor over alleged patent infringement, a sign that imaging AI rivalry is becoming more legal and less purely technical. As the market matures, intellectual property may shape who can scale, partner, or defend a product line.
Patent litigation is often a sign that a market is no longer speculative. In imaging AI, that transition is underway: the leading companies are no longer just racing to prove clinical value, but also to defend the technical foundations of their platforms.
This matters because AI products are increasingly built around proprietary workflows, training data pipelines, and inference architectures that can be difficult to separate cleanly from broader product claims. When a company sues a competitor, it is often trying to protect not only an algorithm, but also market position, investor confidence, and partner relationships.
For health systems, the direct impact may seem distant, but it is not trivial. Legal uncertainty can affect product roadmaps, support commitments, and M&A options. It can also influence whether customers choose a vendor they view as stable and defensible over one that is technically impressive but commercially vulnerable.
The deeper takeaway is that healthcare AI is becoming a real industry, with all the friction that entails. Competition is no longer just about accuracy numbers; it is also about patents, distribution, reimbursement, and durability.